Ron Tintner, M.D.
Co-director, Movement Disorders and Neuro-rehabilitation Center
Methodist Neurological Institute
Department of Neurology
Associate Professor of Neurology
Weill Cornell Medical College
6560 Fannin St. Suit 802
Houston, Texas 77030
Dr Tintner is Co-Director of the Movement Disorders and Neuro-rehabilitation Center in the Department of Nueology. His primary interest consists of movement disorders (Parkinson's, tremor, dystonia, Tourette's) including treatment with botulinum toxin, EMG and motor control and cognitive dysfunction.
Dr Tintner also studies the neurobiologic basis of music perception and performance, and neurologic problems affecting musicians.
- Memory problems
- Movement disorders
- Obsessive compulsive disorder
- Parkinson’s disease
- Tourettes syndrome
- Trigeminal neuralgia
Dr. Tintner’s research involves developing diagnostic and therapeutic modalities for movement disorders such as PD, dystonias, tremor, Tourette syndrome including the use of botulinum toxins for dystonia, chemotherapeutic agents for Parkinson’s disease, and quantitative measures for tremor and mobility. As well as interest and experience in cognitive disorders including, Alzheimer’s disease and ADHD. His support has primarily been for clinical trials.
M.D. - University of Florida
Neurology Residency - Univ. of Texas Health Science Center at Dallas
Movement Disorders Fellowship - Baylor College of Medicine, Houston, TX
Amer. Board of Psychiatry and Neurology
- Tintner R, Gross R, Winzer UF, Smalky KA, Jankovic J. (2005) Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial". Neurology. 65(5):765-7.
- Tintner R, Manian P, Gauthier P, Jankovic J.(2005) "Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease". Arch Neurol. 62(8):1290-5.
- Ashour R, Tintner R, Jankovic J.(2005) "Striatal deformities of the hand and foot in Parkinson's disease". Lancet Neurol. 4(7):423-31.
- Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G. (2005) "Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease". Mov Disord.20(8):958-63.
- Tintner R, Jankovic J. (2003) "Dopamine agonists in Parkinson's disease". Expert Opin Investig Drugs. 12(11):1803-20.